SOURCE: Apexian Pharmaceuticals, Inc.

Apexian Pharmaceuticals, Inc.

October 24, 2016 08:00 ET

ApeX Therapeutics Changes Name to Apexian Pharmaceuticals to Reflect Broader Advancement of Oncology Pipeline

INDIANAPOLIS, IN--(Marketwired - October 24, 2016) - ApeX Therapeutics, a clinical stage biotechnology company focused on developing novel compounds to treat cancer, today announced that it has changed its corporate name to Apexian Pharmaceuticals, Inc. As part of this name change, the company has also launched a new corporate website at and a new Twitter handle @ApexianPharma.

"Now is the time to acknowledge that our key priorities are increasingly focused on advancing our innovative oncology molecules through the clinic," stated Steve Carchedi, President and CEO of Apexian Pharmaceuticals. "We are committed to developing innovative new medicines to extend and enhance the lives of cancer patients. The name change to Apexian Pharmaceuticals is indicative of the great progress we've made in advancing our APE1/Ref-1 targeted drug candidates. Specifically, our recent IND acceptance by the FDA for APX3330 highlights our focus on bringing safe and effective medicines into the clinic."

ApeX Therapeutics recently announced acceptance by the U.S. Food and Drug Administration of an Investigational New Drug Application to evaluate the tolerability and anti-tumor effects of APX3330, a small molecule in development to treat late stage cancer.

About Apexian Pharmaceuticals

Apexian Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel compounds to treat cancer, targeting the multiple functions of the APE1 protein. The lead drug candidate, APX3330, initially targets late stage cancer refractory to existing treatments and is expected to begin clinical studies in 2016. To learn more about Apexian Pharmaceuticals, please visit the Company's website at

Contact Information